Slu-Pp-332 Supplier: Research-Grade Sourcing & Biochemical Analysis

Supplier Overview: Sourcing High-Purity SLU-PP-332

A qualified SLU-PP-332 supplier provides research-grade small-molecule compounds verified through reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry (MS) with complete lot traceability. PX1 Research supplies USA-manufactured SLU-PP-332 featuring ≥98% purity, documented endotoxin testing, and third-party Certificates of Analysis for in vitro and animal model investigations.

When sourcing research compounds for complex metabolic signaling assays, analytical consistency across batches is paramount. Inconsistent purity levels or undetected solvent residues can compromise experimental reproducibility, alter mitochondrial oxidation rates, or distort transcriptomic profiles. PX1 Research operates under strict quality management protocols to ensure that every lot of SLU-PP-332 meets strict specifications prior to dispatch from our California and Arizona fulfillment centers.

Molecular Profile and Mechanism of Action

SLU-PP-332 is a novel synthetic small-molecule agonist specifically designed to target the estrogen-related receptor (ERR) family, with high selectivity for ERRα, ERRβ, and ERRγ isoforms. Unlike classical estrogen receptors (ERα and ERβ), ERRs are orphan nuclear receptors that do not bind endogenous broad-spectrum estrogens directly. Instead, they require synthetic ligands or specific coactivators, such as peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α), to regulate genes governing mitochondrial biogenesis and oxidative phosphorylation.

Preclinical studies indicate that SLU-PP-332 binds to the ligand-binding domain (LBD) of ERRα, inducing a conformational shift that recruits PGC-1α. This recruitment upregulates transcriptional networks responsible for fatty acid oxidation, mitochondrial electron transport chain synthesis, and pyruvate oxidation. Laboratory investigations utilizing cellular models demonstrate that incubation with SLU-PP-332 elevates basal oxygen consumption rates (OCR) and increases maximal respiration without uncoupling ATP synthesis from mitochondrial electron transport.

Preclinical Literature and Experimental Models

Academic literature evaluating SLU-PP-332 has focused primarily on rodent models of metabolic syndrome, muscle fatigue, and lipid homeostasis. In murine trials, administration of SLU-PP-332 demonstrated a significant shift in skeletal muscle fiber type composition toward oxidative Type I and Type IIa fibers, accompanied by an increase in total mitochondrial density within gastrocnemius and soleus tissues.

Furthermore, rodent models evaluating exercise capacity demonstrated that subjects receiving SLU-PP-332 exhibited prolonged run times to exhaustion on treadmills compared to vehicle controls. These biochemical adaptations occurred independently of physical endurance training, suggesting that ERRα stimulation directly activates transcription factors associated with physiological exercise responses. Data gathered from rodent hepatic assays also revealed decreased lipid droplet accumulation and suppressed lipogenic gene expression, establishing SLU-PP-332 as a primary tool for exploring metabolic flux and non-alcoholic fatty liver disease (NAFLD) pathways in vitro.

To explore complementary pathways, investigators frequently evaluate compound classes documented in our comprehensive metabolic research library and broader catalog of research peptides.

Comparative Analysis: SLU-PP-332 vs. Related Metabolic Research Compounds

When evaluating small-molecule modulators of cellular energy metabolism, researchers often compare SLU-PP-332 against established nuclear receptor ligands and mitochondrial regulator peptides. While SLU-PP-332 specifically engages the ERR family, alternative compounds operate via distinct nuclear receptors, circadian machinery, or mitochondrial pathways.

For instance, Cardarine GW501516 acts as a selective Peroxisome Proliferator-Activated Receptor delta (PPAR-δ) agonist, stimulating lipid burning and beta-oxidation pathways through PPAR-dependent transcription factors. Conversely, Stenabolic SR9009 targets Rev-ErbA alpha/beta nuclear receptors to modulate circadian expression of metabolic genes. In contrast to these small molecules, MOTS-c is a mitochondrial-derived peptide that translocates to the nucleus under metabolic stress to regulate folate activation and glucose clearance. Researchers studying oxidative metabolism frequently select between these targeted modalities—or design comparative assays across them—to isolate specific signaling nodes within the PGC-1α transcriptional axis.

Analytical Verification: HPLC, Mass Spectrometry, and Endotoxin Testing

Selecting a high-tier SLU-PP-332 supplier requires rigorous evaluation of vendor analytical standards. PX1 Research subjects every batch of synthetic compounds to independent, third-party laboratory analysis conducted by ISO 17025 accredited facilities. Certificates of Analysis (COAs) are made publicly available per lot number, ensuring absolute transparency for research institutions.

Purity verification begins with reverse-phase high-performance liquid chromatography (RP-HPLC), establishing that the compound meets or exceeds 98.0% chemical purity with minimal synthesis side-products or related impurities. Mass spectrometry (LC-MS) confirms the exact molecular weight and structural identity of the target molecule.

Additionally, for cell culture and in vivo animal research, bacterial endotoxins present a severe confounding variable that can trigger non-specific inflammatory signaling via Toll-like Receptor 4 (TLR4). PX1 Research conducts quantitative Chromogenic Limulus Amebocyte Lysate (LAL) testing to confirm that endotoxin limits remain strictly controlled below standard preclinical thresholds.

Reconstitution, Solubility, and Storage Parameters

SLU-PP-332 is supplied as a highly stable, lyophilized white-to-off-white crystalline powder. Because SLU-PP-332 is a hydrophobic small molecule rather than a hydrophilic peptide, proper solvent selection is essential to achieve complete dissolution and prevent precipitation in experimental working solutions.

In vitro stock solutions are typically prepared using dimethyl sulfoxide (DMSO) or high-purity anhydrous ethanol. SLU-PP-332 demonstrates limited solubility in standard aqueous buffers (such as PBS or saline) without the addition of suitable co-solvents or solubilizers like PEG-400, Tween-80, or cyclodextrins. For cell culture experiments, initial solubilization in 100% DMSO followed by dilution into serum-free culture media (maintaining final DMSO concentrations below 0.1% v/v) prevents cytotoxicity while preserving compound stability.

Lyophilized SLU-PP-332 powder should be stored tightly sealed at -20°C in a desiccated environment away from light exposure. Once reconstituted in organic solvents, aliquots should be stored at -80°C to minimize degradation over extended experimental timelines. Repeated freeze-thaw cycles must be avoided.

Supply Chain Quality and Facility Standards

PX1 Research maintains complete control over synthesis protocols and distribution chains. All compounds are synthesized in state-of-the-art, GMP-compliant facilities located within the United States. Domestic manufacturing eliminates the supply disruptions, international customs holds, and quality control variability associated with unverified overseas suppliers.

Facilities ordering through PX1 benefit from rapid order processing, with same-day shipping offered Monday through Friday from our dedicated logistics centers in California and Arizona. Each shipment is packaged using thermal isolation and secure containers to protect compound integrity against ambient temperature fluctuations during transit. Learn more about our specialized support for university laboratories, contract research organizations, and institutional buyers via our wholesale accounts portal.

Designing Preclinical Protocols with SLU-PP-332

When incorporating SLU-PP-332 into experimental designs, investigators must establish appropriate control parameters. For in vitro cell culture assays, primary cell lines such as C2C12 myotubes, primary hepatocytes, or 3T3-L1 adipocytes are commonly exposed to concentrations ranging from 1 μM to 10 μM over incubation periods of 24 to 48 hours to assess target gene induction (e.g., Pgc-1a, Cpt1b, Acadm).

In animal studies, vehicle selection is critical due to compound lipophilicity. Typical vehicles reported in literature utilize mixtures of 10% DMSO, 40% PEG-300, 5% Tween-80, and 45% saline to achieve stable parenteral suspension. Detailed methodologies and target pathways can be explored further in our estrogen-related receptor agonists review.